Solbec completes Phase I psoriasis trial
Wednesday, 09 February, 2005
Solbec Pharmaceuticals (ASX: SBP) has announced successful completion of its Phase I study of its devil's apple-derived drug Coramsine as a treatment for psoriasis.
Preliminary results from the trial, which incorporated two stages to look at the safety and tolerability in healthy individuals, plus a third stage to assess efficacy in ten patients with psoriasis, indicate that there were no treatment-related adverse events during the trial. The drug was administered in a cream formulation and in the efficacy stage of the trial, was compared to both placebo and to a standard treatment for psoriasis over a period of 56 days.
The company said efficacy results would be reported in the second quarter of this year, once the trial has been unblinded and data analysed.
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
Life expectancy gains are slowing, study finds
Life expectancy at birth in the world's longest-living populations has increased by an...
Towards safer epilepsy treatment for pregnant women
New research conducted in organoids is expected to provide pregnant women with epilepsy safer...
